We are excited to progress the collaboration with Sysmex and look forward to a fruitful long-term partnership together. Learn more: tinyurl.com/mt9jbj3n

Following the successful transfer of our Nu.Q® NETs assay onto @SysmexEurope platform we are delighted to commence the optimization phase in diseases associated with NETosis. NETosis is implicated in a wide range of diseases, including sepsis and other acute and chronic diseases. Learn more: tinyurl.com/mt9jbj3n

This new paper advances our understanding of #sepsis and #NET formation as a whole and could facilitate the discovery of new therapeutic targets and diagnostics to look at these precise signals. Now available on Frontiers in Immunology Research Network: tinyurl.com/5absa6md

Volition has announced a new patent filing protecting the use of Nu.Q® NETs for Ebola triage and treatment monitoring, expanding the potential application of nucleosome biomarkers in infectious disease management. More: tinyurl.com/mtbbz9rk

New milestone for Nu.Q® NETs: we have filed a new patent protecting the use of Nu.Q® NETs for Ebola triage and treatment monitoring. More information here: tinyurl.com/mtbbz9rk

Progress continues for our Nu.Q® NETs assay, with inclusion in the DETECSEPS program, a government-backed initiative in France focused on improving early sepsis detection and enabling more personalized patient care. We also announced two additional potential clinical applications beyond sepsis: acute trauma care and Hidradenitis Suppurativa (HS). Together, these emerging use cases highlight the broad potential of Nu.Q® NETs across both acute and chronic disease settings. Learn more: tinyurl.com/ytzdepxk

#ICYMI: manuscript for Nu.Q® Vet Cancer Test in Cats now available on SSRN: tinyurl.com/cab6tpxc

#ICYMI: This study, part of the SUMMIT program, tested capillary blood samples from hospital patients in Intensive Care using a lateral flow finger-prick prototype and demonstrated the detection of nucleosomes in those samples. Learn more: tinyurl.com/5sbucydc

This finger prick sample test could be used at the bedside, in the ER, or even at home in a self-test lateral flow kit, similar to COVID-19 or pregnancy testing, thereby greatly expanding the potential market beyond centralized lab testing. Learn more: tinyurl.com/5sbucydc

Volition: Acceptance of Compliance Plan by NYSE American Learn more: tinyurl.com/ycyjwf7n

We were pleased to be featured in Dr Nabeshima presentation at JCVIM this year. Find out more about the presentation titled 'Utility of Nucleosome Concentration in Differentiating Canine Gastrointestinal Lymphoma from Chronic Intestinal Disease' here: tinyurl.com/bddxwksc

Volition: Full Fiscal Year 2025 Financial Results and Business Update now on our website. Read here: tinyurl.com/3xh94e9r Join our conference call today at 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time to discuss the results: tinyurl.com/46892wzs

Volition presents new data at #ELCC demonstrating how Nu.Q® Cancer assay can support risk stratification in lung cancer patients. “A key finding from this study was that measuring preoperative H3K27Me3-nucleosomes using Volition’s simple blood test allows us to identify which Non Small Cell Lung Cancer patients are most likely to benefit from closer follow-ups or secondary cancer treatment." More information: tinyurl.com/yfy3brnj Download poster: tinyurl.com/3mhm57rb #LungCancer

"From a clinical perspective, the proof of concept and early blinded validation results are extremely encouraging, and the early-stage cancer detection of 95% of stage I and II cancers is particularly noteworthy. "For patients, the potential significance is huge. If validated in larger cohorts, CTCF Capture-Seq™ could contribute to Multi-Cancer Early Detection (MCED) fulfilling a significant unmet clinical need," commented Dr. Andrew Retter, Medical Consultant, Volition

NEWS: Volition Announces Detection of Over 95% of Early-Stage Cancers ➡️Blinded validation cohort achieves over 95% sensitivity for stage I & II cancers with 95% specificity More information: tinyurl.com/4es4nasr Watch video: tinyurl.com/fr8693kk

ICYMI: Volition's new method produced >99% pure ctDNA sequencing data sets for blood samples from cancer patients and, whilst we capture a subset of the ctDNA (i.e. not all the ctDNA in a sample), it is virtually pure cancer DNA. These methodological and technological breakthroughs represent a novel liquid biopsy method for a novel class of potentially thousands of liquid biopsy sequence biomarkers. More: tinyurl.com/kfcccyrp

The biggest problem facing liquid biopsy worldwide is that the vast majority of circulating DNA in blood plasma samples comes from healthy cells, not cancer cells. In a world first new technology, Volition has overcome this hurdle and produced >99% pure cancer derived plasma DNA sequence sets for liquid biopsy. Read press release now: tinyurl.com/kfcccyrp